On December 4, 2024, Eric Karas, the Chief Commercial Officer of ARS Pharmaceuticals Inc, sold 10,000 shares of the company, according to a SEC Filing. Following this transaction, the insider now owns 5,693 shares of the company.
ARS Pharmaceuticals Inc (SPRY, Financial) is a biopharmaceutical company focused on developing novel therapies for the treatment of allergic reactions. The company's lead product candidate is designed to provide rapid relief from severe allergic reactions, including anaphylaxis.
The insider's recent sale is part of a broader trend observed within the company. Over the past year, Eric Karas has sold a total of 30,000 shares and has not made any purchases. The overall insider transaction history for ARS Pharmaceuticals Inc indicates that there have been 1 insider buy and 55 insider sells over the past year.
On the day of the recent sale, shares of ARS Pharmaceuticals Inc were trading at $14.04 each, giving the stock a market cap of $1.401 billion. Investors may consider various valuation metrics such as the GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow when evaluating the stock.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
